2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma

Leukemia Research

Volumn 34, Issue 2, 2010, Pages 184-189

  Orciuolo, Enrico ^a   Buda, Gabriele ^a   Sordi, Elisabetta ^a   Baraté, Claudia ^a   Galimberti, Sara ^a   Ciancia, Eugenio ^b   Petrini, Mario ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

2CdA; Marginal zone lymphoma; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

AMOXICILLIN; ANTIHISTAMINIC AGENT; CD20 ANTIBODY; CLADRIBINE; CLARITHROMYCIN; PARACETAMOL; PROTON PUMP INHIBITOR; RITUXIMAB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL EFFECTIVENESS; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TARGETING; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HEMOLYSIS; HERPES ZOSTER; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MINIMAL RESIDUAL DISEASE; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NODAL MARGINAL ZONE LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PYREXIA IDIOPATHICA; RETROSPECTIVE STUDY; SPLENIC MARGINAL ZONE LYMPHOMA; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 74849118877     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2009.04.003     Document Type: Article

References (27)

1. Ferreri A.J., and Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 63 (2007) 245-256
2. Project T.N.-H.s.L.C. The non-Hodgkin's lymphoma classification project: a clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89 (1997) 3909-3918
3. Berger F., Felman P., Thieblemont C., Pradier T., Baseggio L., Bryon P.A., et al. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 95 (2000) 1950-1956
4. Arcaini L., Lazzarino M., Colombo N., Burcheri S., Boveri E., Paulli M., et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 107 (2006) 4643-4649
5. Thieblemont C. Non-MALT marginal zone lymphomas. Ann Oncol 4 19 Suppl. (2008) iv70-iv73
6. Thieblemont C., and Coiffier B. Management of marginal zone lymphomas. Curr Treat Options Oncol 7 (2006) 213-222
7. Pinotti G., Zucca E., Roggero E., Pascarella A., Bertoni F., Savio A., et al. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma 26 (1997) 527-537
8. Hammel P., Haioun C., Chaumette M.T., Gaulard P., Divine M., Reyes F., et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 13 (1995) 2524-2529
9. Levy M., Copie-Bergman C., Traulle C., Lavergne-Slove A., Brousse N., Flejou J.F., et al. Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome. Am J Gastroenterol 97 (2002) 292-297
10. Lefrere F., Hermine O., Belanger C., Francois S., Tilly H., Lebas de La Cour J.C., et al. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 14 (2000) 573-575
11. Zinzani P.L., Stefoni V., Musuraca G., Tani M., Alinari L., Gabriele A., et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 100 (2004) 2190-2194
12. Jager G., Neumeister P., Brezinschek R., Hinterleitner T., Fiebiger W., Penz M., et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 20 (2002) 3872-3877
13. Riccioni R., Caracciolo F., Galimberti S., Cecconi N., and Petrini M. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 21 (2003) 163-168
14. Jager G., Hofler G., Linkesch W., and Neumeister P. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chloro-deoxyadenosine (2-CDA) treatment of a low-grade gastrointestinal MALT lymphoma case report and review of the literature. Haematologica 89 (2004) ECR01
15. Conconi A., Martinelli G., Thieblemont C., Ferreri A.J., Devizzi L., Peccatori F., et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 102 (2003) 2741-2745
16. Martinelli G., Laszlo D., Ferreri A.J., Pruneri G., Ponzoni M., Conconi A., et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 23 (2005) 1979-1983
17. Kalpadakis C., Pangalis G.A., Dimopoulou M.N., Vassilakopoulos T.P., Kyrtsonis M.C., Korkolopoulou P., et al. Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol 25 (2007) 127-131
18. Brown J.R., Friedberg J., Feng Y., Phillips K., Clark J.C., Dal Cin P., et al. A phase II study of fludarabine and rituximab for the treatment of marginal zone lymphomas. Blood 110 (2007) 408a [abstract 1358]
19. Delannoy A. 2-chloro-2'-deoxyadenosine: clinical applications in hematology. Blood Rev 10 (1996) 148-166
20. Sigal D.S., and Saven A. Cladribine in indolent non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 8 (2008) 535-545
21. Matutes E., Oscier D., Montalban C., Berger F., Callet-Bauchu E., Dogan A., et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 22 (2008) 487-495
22. Cheson B.D., Pfistner B., Juweid M.E., Gascoyne R.D., Specht L., Horning S.J., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 25 (2007) 579-586
23. Garcia-Suarez J., de Miguel D., Krsnik I., Banas H., Arribas I., and Burgaleta C. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies. Am J Hematol 80 (2005) 271-281
24. Bertoni F., and Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 23 (2005) 6415-6420
25. Franco V., Florena A.M., and Iannitto E. Splenic marginal zone lymphoma. Blood 101 (2003) 2464-2472
26. Lefrere F., Hermine O., Francois S., Panelatti G., Valensi F., Grosbois B., et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 40 (2000) 113-117
27. Tsimberidou A.M., Catovsky D., Schlette E., O'Brien S., Wierda W.G., Kantarjian H., et al. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer 107 (2006) 125-135